BRAF and cancer: Taking into account the positive binding results obtained in the docking studies to the BRAF-ATP model and the promising cytotoxicity shown in several cancer cells, we next explored the effect of compounds with IC50 near to that of sorafenib (1, 2, 3, 4, 9, and 52) on the MAPK/ERK pathway.